The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Dummy sell 28.2
Was hoping to fill a last little gap, 10,000 @ 23p, doesn't look like I'll get chance now.
Try now, 26.5 has just cleared on L2.
Been trying to buy for the last 10minutes with Halifax
Nt for small purchases
Doesnt look like it
Does RF still need to clear out their shares?
Perhaps the blue touch paper has been lit?
Exactly Lazarus 2, it's that research that keeps me believing in Sareum and many thanks to those who share such.
@ Celtic no offence and I appreciate your support of this bb, but, was there any need to bring FG into this thread - gives him an opportunity to work his agenda!
GLA
Morning Celtic - that's just how business works sometimes. We just have to wait and see.
Exactly ...Lazarus. great research and so nice to have all the septic people nearly out of here. See funny guy still here, like a bad fart, but the data released soon going to act like a deodorant to neutralise him and his shorting bricks
The research on this board is second to none and is a major confidence boost to those of us believing in the future of Sareum.
Stars and ducks are aligning I feel and, irrespective of market shenanigans, true value will eventually be established. Thank you all for sharing.
SRA737 for prostate cancer
“SRA737 exhibiting remarkable single agent anticancer activity”
Exactly right. The average licencing deal for platform and discovery candidates in 2023 was $47 million and $55 Million respectively. The $63 million KYM licencing deal for its P1 candidate was at a slight premium to that.
* The average Phase 2 upfront licencing payment in our sector was much higher at $310 million in 2023.
* In the not too distant future we could be waking up to an RNS announcing a licencing deal for SDC-1801. Why would anyone want to miss out on that opportunity?
See the link to the full report on up front payments for licencing deals in our sector in 2023 below...
Good luck, Brighty
https://www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpmorgan-dec-2023-biopharma-licensing-and-venture-report.pdf
Apologies if already posted
https://www.researchgate.net/publication/377699214_Synthetic_lethal_combination_of_CHK1_and_WEE1_inhibition_for_treatment_of_castration-resistant_prostate_cancer
Last year AstraZeneca entered in to an agreement with KYM Biosciences for its Phase I clinical candidate CMG901. AZ paid an upfront payment of $63m and agreed additional milestone development and sales-related payments of up to $1.1bn.
Beware of the devious or ignorant on this chat forum who have no comprehension of the significant upside big pharma will pay for a new P1 candidate such as SDC-1801.
Good morning Bobbler,
Excellent post and an important link.
It maybe worthwhile noting thst Acrivon has been designated fast track in endometrial and breast cancer ( 2023). Prexasertib and IV admistered chk1 2 inhibitor.
https://www.cancernetwork.com/view/fda-grants-ftd-to-prexasertib-in-ovarian-endometrial-cancers
Future is very bright for Chk1 inhibitors in combo therapy. On its own it is effective in what it us designed to do but needs assistance from DNA damaging agents eg gemcitabine.
Regards
Great research thank you. Am sure this company makes a asthma drug called spiriva as well . Thank you . Big German pharmaceutical....a beast you would say
Amazing research and a very big thank you. Add this drug (737) to 1801 and it goes some way to show Sareum have assets that can really make a difference to people’s lives. Let alone the company. Well done indeed.
HBD ref SRA737, I think the partner could possibly be Boehringer Ingelheim US subsidiary, technically this is a private US based company, ultimately owned by the parent in Germany. Boehringer Ingelheim Inc will have issued shares (private) and could therefore offer them as part of the deal.
Boehringer Ingelheim Collaborate extensively with Cancer Research Technology (trading as Cancer Research Horizons).
Full Disclosure of interactions with industry:
Sometimes, through Cancer Research Technology Limited, Cancer Research UK will receive shares rather than financial payments when research partnerships are created. Cancer Research UK does not usually apply a market value to such shareholdings but some information concerning these shareholdings can be found in Cancer Research Technology Limited’s statutory accounts filed at Companies House.
Boehringer are significantly involved in combo trials of xentuzumab with other drugs.
https://pubmed.ncbi.nlm.nih.gov/37308971/
Researchers based at the University of Oxford have discovered a way to boost the effectiveness of a new type of drug, called xentuzumab, which is currently being tested for breast cancer.
They found that xentuzumab was most effective when combined with drugs MK-8776 and SRA737, which block a protein called CHK1, and AZD1775 that blocks WEE1 protein.
https://breastcancernow.org/about-us/research-news/researchers-discover-way-boost-effectiveness-new-breast-cancer-drug/
Hi hot. Selling on? Is that good for us? Might we mot get the full value?
Hi Lsesar - having completed P2 trials in combo, the BoD may have presumed 737 was at a point in its development that would attract larger upfront payments upon further licensing. Seems perfectly reasonable to me based on what I've read regarding deals for potentially P3-ready compounds. So who here expected a near carbon-copy of the Sierra deal?
Celtic - it's near enough 4mths since the license was announced and there isn't even a hint of who has it in any corner of the internet. For all we know it's been renamed and is currently undergoing preclinical research in combination with other drugs prior to trials in humans.
I keep looking on the US clinical trials website for any newly registered trials mentioning chk1 or anything that could be linked to 737 - nothing to report so far.
We can't even say for sure if our own BoD know who has it. You'd have thought the US firm would announce the deal in a 'look at us! see what we're doing now!' kind of way. I can only hope bigger games are being played behind the scenes and we'll all be pleasantly surprised when we know what's really going on.
Although Potnak suggests it might be with a small company looking to do a bit of work on it before selling it on (which is plausible), I'd be surprised if the CPF picked a small company over a larger pharma to progress 737 (assuming large pharma were interested).
In a nutshell, I'm stumped.
I just hope any negotiations are done with proper advisors who have a excellent track record. The bod have proven to me that they can’t do any licensing/ partner deals alone.
Hbd - I think the reality was that the bod were reliant on a buoyant share price and fully intended to drawn down every penny of the RF funding - we all know how that panned out. I can’t see how they could think that 737 would provide enough funding. I think it is more naivety and poor management perhaps?
The problem with partnerships and licensing deal is that I see this becoming a long drawn out trip to achieve real gains . We already have a deal with 10s of millions in milestone payments but here we are languishing . Honestly the bod need to take a reality check and do the “right” deal. Maybe given that most of us hold more shares than they do, they are not so driven?